1 citations
,
September 2024 in “Life” Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.
July 2022 in “British Journal of Dermatology” 2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
July 2024 in “Reactions Weekly” 4 citations
,
January 1989 1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
5 citations
,
July 2017 in “Skin appendage disorders” A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
September 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Intermittent isotretinoin can cause various skin, hair, and nail changes.
6 citations
,
June 2009 in “Clinical and Experimental Dermatology” Topical tacrolimus reduces certain growth factors in hair follicles.
3 citations
,
February 2024 in “Patient Preference and Adherence” Isotretinoin treatment in Palestine shows poor adherence to guidelines, with common side effects and a need for better prescribing practices and patient education.
15 citations
,
January 2016 in “Dermatologic Clinics” Start acne treatment early to prevent scarring, consider antibiotic resistance, use maintenance therapy, and manage side effects carefully.
59 citations
,
January 2015 in “Nanoscale” The new micelle formulation delivers acne treatment more effectively and safely than current gels.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
January 2026 in “Dermatology and Therapy”
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
24 citations
,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
34 citations
,
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Azelaic acid is effective for treating rosacea, acne, and melasma.
1 citations
,
January 1980 in “Acta Dermato Venereologica” Oral tetracycline reduces fat breakdown in hair lipids.
September 2024 in “Journal of the American Academy of Dermatology” The new hair treatment significantly reduces hair shedding safely.
March 2025 in “SKIN The Journal of Cutaneous Medicine”
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Many people in Jordan misuse topical steroids without proper knowledge, highlighting the need for better education and regulation.
August 2018 in “Journal of The American Academy of Dermatology” Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.